MARKET

NVIV

NVIV

InVivo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2700
+0.0019
+0.71%
After Hours: 0.2782 +0.0082 +3.04% 17:37 01/17 EST
OPEN
0.2939
PREV CLOSE
0.2681
HIGH
0.2939
LOW
0.2501
VOLUME
557.77K
TURNOVER
--
52 WEEK HIGH
1.789
52 WEEK LOW
0.1231
MARKET CAP
4.46M
P/E (TTM)
-0.2281
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NVIV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NVIV News

  • The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug
  • Benzinga.11/26/2019 13:06
  • The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate
  • Benzinga.11/22/2019 13:18
  • The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate
  • Benzinga.11/22/2019 13:18
  • Mid-Afternoon Market Update: Cubic Tumbles Following Q4 Results; Hepion Pharmaceuticals Shares Climb
  • Benzinga.11/21/2019 19:42

More

Industry

Advanced Medical Equipment & Technology
+0.57%
Healthcare Equipment & Supplies
+0.29%

Hot Stocks

Name
Price
%Change

About NVIV

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
More

Webull offers Invivo Therapeutics Holdings Corp (NVIV) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.